16th week of 2015 patent applcation highlights part 43 |
Patent application number | Title | Published |
20150105297 | Electrical Polynucleotide Mapping - A micro-fluidic device for mapping a DNA or RNA strand labeled at a plurality of specific sites with labels suitable for generating a detection signal when interacting with a detector element, the device comprising:
| 2015-04-16 |
20150105298 | MULTI-OLIGOMER IN SITU HYBRIDIZATION PROBES - The disclosure relates to in situ hybridization probes for the detection of target nucleic acid sequences within a sample and methods of making and using the same. The in situ hybridization probes of the current disclosure include a plurality of nucleic acid elements capable of selectively hybridizing to at least a portion of a nucleic acid of interest and/or other nucleic acid elements of the in situ hybridization probe, which enable the detection of a target nucleic acid. The current disclosure also relates to kits which incorporate the in situ hybridization probe compositions of the instant disclosure. | 2015-04-16 |
20150105299 | Method for Differentiation of Polynucleotide Strands - Objective of the present invention is to provide a method for keeping of directional information in double-stranded DNA. We suggest to convert polynucleotide into a hybrid double-stranded DNA. One particular strand of this hybrid double-stranded DNA should be synthesised using at least one modified nucleotide. Thus, this particular strand would contain modified nucleotides along the whole length. Density of directional markers would not depend on the length of polynucleotides. Any internal fragments of the hybrid double-stranded DNA would have directional information. When it is necessary the modified strand may be easily degraded or separated from the other strand. It was found that such hybrid double-stranded DNA may be easily generated in a number of molecular biology tasks and may be used for molecular cloning, library preparation and strand separation. | 2015-04-16 |
20150105300 | Sample Processing Methods - A method of processing a sample may include introducing a sample into a vessel, the vessel having proximal and distal ends, the sample being introduced into the proximal end of the vessel; incubating the sample in the vessel with a substance capable of specific binding to a preselected component of the sample; propelling components of the incubated sample, other than the preselected component, toward the proximal end of the vessel by clamping the vessel distal to the incubated sample and compressing the vessel where the incubated sample is contained; propelling the preselected component toward a distal segment of the vessel by clamping the vessel proximal to the preselected component and compressing the vessel where the preselected component is contained; and mixing the preselected component with a reagent in the distal segment of the vessel. | 2015-04-16 |
20150105301 | ALKOXY CARBOXYLATE SURFACTANTS - Provided herein are inter alia novel compositions and methods having application in a variety of fields including the field of enhanced oil recovery, the cleaning industry as well as groundwater remediation. In particular, the alkoxy carboxylate compounds and mixtures thereof presented herein can be used, inter alia, for the recovery of a large range of crude oil compositions from challenging reservoirs. | 2015-04-16 |
20150105302 | SYSTEMS, METHODS, AND COMPOSITIONS COMPRISING AN EMULSION OR A MICROEMULSION AND CHLORINE DIOXIDE FOR USE IN OIL AND/OR GAS WELLS - The present invention generally provides systems, methods, and compositions comprising an emulsion or a microemulsion and chlorine dioxide for use in oil and/or gas wells. In some embodiments, the systems, methods, and/or compositions comprise reducing the viscosity a fluid comprising a polymer, wherein the fluid was utilized in the recovery of oil and/or gas from the oil and/or gas well. | 2015-04-16 |
20150105303 | GYPSUM SCALE INHIBITORS FOR ORE SLURRY SYSTEMS IN HYDRO-METALLURGICAL APPLICATIONS - The current technology relates to mining processes and compositions which inhibit the growth of complex scale. More specifically it relates to a process for preventing/inhibiting and/or controlling gypsum scale in aqueous mineral ore slurries, and for inhibiting scale in relatively high solids content environments in industrial mining operations. | 2015-04-16 |
20150105304 | GREASE COMPOSITION,GREASE-PACKED BEARING, UNIVERSAL JOINT FOR PROPELLER SHAFT, LUBRICATING OIL COMPOSITION, AND OIL-IMPREGNATED SINTERED BEARING - The present invention provides a grease composition or a lubricating oil composition which is capable of effectively preventing hydrogen brittleness-caused peeling from occurring on a rolling surface of a rolling bearing, is excellent in durability in a high temperature and speed operation, and can be used for a long time. A grease-packed bearing ( | 2015-04-16 |
20150105305 | High Elastohydrodynamic Shear Strength Fluid Compositions - A lubrication fluid including cyclic hydrocarbons in combination with dimethylsilicone fluids and/or di-alkyl or di-cycloalkyl or alkyl-cycloalkyl, or mixtures thereof, and di-end-capped polypropylene oxides or highly branched esters to produce very high traction elastohydrodynamic (EHD) traction fluids and to modify the low temperature viscometric properties of the mixed fluids without adversely affecting the very high elastohydrodynamic shear strength or traction coefficients of the very high shear strength cyclic hydrocarbon fluid in the resulting mixed fluids with improved low temperature viscosity. | 2015-04-16 |
20150105306 | MANNICH CONDENSATION PRODUCTS AS SEQUESTERING AGENTS FOR FUELS AND LUBRICATING OILS - Sequestering agents for use in fuels and lubricating oils derived from Mannich condensation reaction utilizing a polyisobutyl-substituted hydroxyaromatic compound, an aldehyde, an alkali metal base, and glycine or aspartic acid, or an ester thereof. | 2015-04-16 |
20150105307 | TERPOLYMER-COATED POLYMER ENCAPSULATED ACTIVE MATERIAL - A polymeric encapsulated fragrance is disclosed which is suitable for use in personal care and cleaning products. In a preferred embodiment of the invention the fragrance is encapsulated by a first polymer material to form a fragrance encapsulated polymer, the polymer encapsulated shell is then coated with a cationic polymer, preferably a terpolymer composed of methacrylamidopropyl trimethyl ammonium chloride, acrylamide and acrylic acid. | 2015-04-16 |
20150105308 | Aqua Regia and Hydrogen Peroxide HCl Combination to Remove Ni and NiPt Residues - A method for cleaning residues from a semiconductor substrate during a nickel platinum silicidation process is disclosed, including a multi-step residue cleaning, including exposing the substrate to an aqua regia solution, followed by an exposure to a solution having hydrochloric acid and hydrogen peroxide. The SC2 solution can further react with remaining platinum residues, rendering it more soluble in an aqueous solution and thereby dissolving it from the surface of the substrate. | 2015-04-16 |
20150105309 | Powdered Automatic Dishwashing Detergent - This disclosure relates to powdered automatic dishwashing detergents. More particularly, this disclosure relates to powdered automatic dishwashing detergent packets with superior environmental and human safety as well as superior cleaning efficacy and stability. | 2015-04-16 |
20150105310 | Laundry Additives from Crude Protein Sources - Modified protein compositions that provide benefits in laundry products are produced by minimal processing of crude protein sources. Modifications include reaction with one or more of 1) cationic functional agents, 2) anionic functional agents, 3) proteolytic enzymes, 4) redudng agents and 5) oxidizing agents. They may be complexed with a surfactant to improve the separation from insoluble cellulosic carbohydrate materials in the crude protein sources, and to improve their dispersibility and effectiveness in laundry products. The resulting products may provide benefits of preventing soil redeposition, preventing dye transfer, soil repellency, and fabric wear reduction in laundry operations. The invention also encompasses the laundry products comprising the protein compositions. | 2015-04-16 |
20150105311 | FLUID LAUNDRY DETERGENT COMPOSITION - Compact fluid laundry compositions comprising polymer deposition aids and multivalent water-soluble builders and/or chelants can be stabilized using external structurant systems. | 2015-04-16 |
20150105312 | Colored Speckles For Use In Granular Detergents - This invention relates to non-bleeding, non-staining colored speckles for use in granular or powdered detergents such as laundry detergents and automatic dishwashing detergents. The colored speckles are comprised of a salt or salt-containing carrier and a coloring agent and are characterized as being substantially uniformly colored throughout the cross-sectional volume of the speckle. | 2015-04-16 |
20150105313 | HIGHLY CONCENTRATED LIQUID WASHING OR CLEANING COMPOSITION - The application describes a highly concentrated, liquid washing or cleaning agent which contains a) 18 to 35 wt. %, relative to the entire washing or cleaning agent, of anionic surfactant of the sulfonate type selected from the group consisting of C | 2015-04-16 |
20150105314 | BIODEGRADABLE STABILITY BINDING AGENT FOR A SOLID DETERGENT - A solid composition includes a polysaccharide hybrid polymer composition and a hydratable salt. In one embodiment, the polysaccharide hybrid polymer composition includes a polysaccharide residue present in an amount from approximately 5% to 90% by weight of the polysaccharide hybrid polymer composition and a residue of at least one ethylenically unsaturated monomer present in an amount from approximately 10% to 75% by weight of the polysaccharide hybrid polymer composition. | 2015-04-16 |
20150105315 | Polypeptide Fragments Comprising Endonuclease Activity and Their Use - The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting. This invention also relates to compounds and pharmaceutical compositions comprising the identified compounds for the treatment of disease conditions due to viral infections caused by viruses of the Orthomyxoviridae family. | 2015-04-16 |
20150105316 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof - This application describes compounds acting as, for example, β-arrestin effectors and uses thereof, in, for example, the treatment of chronic and acute cardiovascular diseases. | 2015-04-16 |
20150105317 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES - Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A. | 2015-04-16 |
20150105318 | ANTIDIABETIC MEDICATIONS - Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others. | 2015-04-16 |
20150105319 | DURABLE HAEMOSTATIC SCAFFOLD - A method for preparing a haemostatic and adhesive durable scaffold useful for promoting wound healing, and the scaffold so prepared, are provided. The scaffold made of fibrinogen and chitosan is produced by electrospinning techniques, resulting in a material with enhanced endurance, applicable in various medical purposes including surgery, tissue regeneration, burns, injuries, and the like. The scaffold is produced in the absence of biocatalysts, in particular thrombin. | 2015-04-16 |
20150105320 | ANTI-ANGIOGENIC TREATMENT OF OVARIAN, BREAST, AND PROSTATE CANCER WITH A COMBINATION OF ANTAGONISTS - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12). | 2015-04-16 |
20150105321 | COAGULATION FACTOR VII POLYPEPTIDES - The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment. | 2015-04-16 |
20150105322 | Non-N-Glycosylated Recombinant Human Annexin A2 - Methods for the expression and purification of non-N-glycosylated human Annexin A2 in yeast, e.g., in | 2015-04-16 |
20150105323 | COLLAGEN COMPOSITIONS AND METHODS OF USE - The present disclosure provides an engineered collagen composition comprising collagen, wherein the collagen composition is compressed to form a gradient of at least one physical property. Methods of using and of manufacturing the engineered collagen compositions of the present disclosure are also provided. | 2015-04-16 |
20150105324 | COMPOSITIONS AND METHODS FOR TREATING PTSD AND RELATED DISEASES - The invention described herein pertains to compositions and methods for treating PTSD and related diseases. In particular, the invention described herein pertains to compositions and methods for treating PTSD and related diseases by administering modulators of NMDA NR2-PSD95-nNOS signaling. | 2015-04-16 |
20150105325 | RECOMBINANT ALPHA-FETOPROTEIN AND COMPOSITIONS THEREOF - Disclosed are pharmaceutical and synergistic compositions comprising human recombination alpha-fetoprotein expressed in eukaryotic cells for preparation of therapeutic agents for use in oncology, immunotherapy, stem cell therapy and cosmetology and also for the diagnosis of cancer and embryonic pathologies. | 2015-04-16 |
20150105326 | METHYL DEGRON PEPTIDE AND METHODS OF CONTROLLING PROTEIN LIFESPAN - The present invention provides an isolated methyl degron peptide and a fusion protein comprising a methyl degron peptide. Also, the present invention provides screening methods for agents affecting protein lifespan and anti-cancer agents. Moreover, the present invention provides methods of controlling protein lifespan, regulating protein expression, and treating cancers by using a methyl degron peptide or a methyl degron gene. | 2015-04-16 |
20150105327 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS - This disclosure provides methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity. Also provided are methods of determining the effectiveness of the methods and compositions to inhibit or suppress tumor growth or to treat cancer by inhibiting VprBP kinase activity, methods for detecting a cancer, and methods for screening potential agents that inhibit VprBP kinase activity. | 2015-04-16 |
20150105328 | PEPTOID-PEPTIDE HYBRIDS AND THEIR USE - The invention concerns peptoid-peptide hybrids that may act as protein interaction inhibitors (PPIIs). Another aspect of the invention concerns a method for treating a disorder (e.g., an oncologic disorder) in a human or animal subject, comprising administering an effective amount of a peptoid-peptide hybrid (a peptoid body) of the invention, or a composition comprising a peptoid-peptide hybrid, to the subject in need thereof. Another aspect of the subject invention concerns a method for killing or inhibiting the growth of cells (e.g., cancer cells or malaria-infected cells), comprising contacting a cancer cell in vitro or in vivo with an effective amount of a peptoid-peptide hybrid, or a composition comprising the peptoid-peptide hybrid. Another aspect of the invention concerns a method for producing a peptoid-peptide hybrid. | 2015-04-16 |
20150105329 | Methods and Pharmaceutical Compositions for Prevention or Treatment of Ischemia Related Organ Damage - The present invention relates to methods and compositions for the prevention or treatment of ischemia related organ damage. | 2015-04-16 |
20150105330 | ACTIVE MIXTURES - Suggested is an active mixture comprising
| 2015-04-16 |
20150105331 | HIGH-PURITY CYCLOPEPTIDE CRYSTAL AS WELL AS PREPARATION METHOD AND USE THEREOF - A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal. | 2015-04-16 |
20150105332 | SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: a) 20-50 wt. % of at least one diacyl glycerol; b) 20-54 wt. % of at least one phosphatidyl choline (PC); c) 5-15 wt. % of at least one biocompatible, organic mono-alcoholic solvent; d) 1 to 20 wt. % polar solvent e) 5 to 150 mg/ml of at least one peptide somatostatin receptor agonist comprising pasireotide; f) optionally at least one antioxidant; wherein the ratio of components a:b is in the range 40:60 to 54:46; wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with excess aqueous fluid. The invention further relates to methods of treatment comprising administration of such compositions, and to pre-filled administration devices and kits containing the formulations. | 2015-04-16 |
20150105333 | LATENT HUMAN IMMUNODEFICIENCY VIRUS REACTIVATION - Provided herein are methods or reactivating a latent Human Immunodeficiency Virus (HIV) infection in a cell. The methods comprise modulating a level of NF-κB activity in the cell by contacting the cell with an agent that produces a transient first increase in the level of NF-κB activity without a second delayed increase in NF-κB activity. Optionally, a second agent is used to prime the reactivation. Also provided herein is an isolated | 2015-04-16 |
20150105334 | PEPTIDES DERIVED FROM NKP44 - The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer. | 2015-04-16 |
20150105335 | NOVEL PEPTIDE COMPOSITIONS - The present invention provides, among other things, novel peptides and compositions for treating disease. | 2015-04-16 |
20150105336 | MUCOSA-ELEVATING AGENT - Provided is a mucosa-elevating agent containing 0.1% to 1.0% of a peptide, wherein the peptide is an amphipathic protein having 8 to 200 amino acid residues in which hydrophilic amino acids and hydrophobic amino acids are alternately bonded, and is a self-assembling peptide that exhibits a β structure in an aqueous solution at physiological pH and/or in the presence of cations. | 2015-04-16 |
20150105337 | ENTEROBACTIN CONJUGATES AND USES THEREOF - The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful in delivering a cargo to a bacterium, treating a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, preventing a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, inhibiting the growth of or killing a bacterium, or determining the concentration of a bacterium in a biological sample. In certain embodiments, the bacterium is a Gram-negative bacterium. | 2015-04-16 |
20150105338 | THERAPEUTIC COMPOSITIONS COMPRISING PHENOLIC ACIDS FOR TREATING CONDITIONS RELATED TO INAPPROPRIATE PLATELET AGGREGATION - The invention provides compositions comprising a therapeutically effective amount of a compound of general formula (I): wherein R1, R2 and R3 may be independently selected from H, OH and OMe; wherein X is C | 2015-04-16 |
20150105339 | METHODS FOR TREATING RESISTANT DISEASES USING TRIAZOLE CONTAINING MACROLIDES - Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating diseases caused at least in party by resistant bacteria. | 2015-04-16 |
20150105340 | TOPICAL AVERMECTIN FORMULATIONS AND METHODS FOR ELIMINATION AND PROPHYLAXIS OF SUSCEPTIBLE AND TREATMENT RESISTANT STRAINS OF HEAD LICE - An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice ( | 2015-04-16 |
20150105341 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs. | 2015-04-16 |
20150105342 | IN VITRO METHOD FOR PREDICTING DISEASE OUTCOME IN STAGE II COLORECTAL CANCER - The present invention relates to a method for determining the likelihood of disease outcome of a patient diagnosed with microsatellite stable, stage II colorectal cancer. More in particular, the present invention relates to a method for determining the prognosis of a patient diagnosed with microsatellite stable, stage II colorectal cancer wherein the CpG island methylation status of the promoter of the CHFR gene is determined and wherein methylation of the promoter is indicative of a poor prognosis. | 2015-04-16 |
20150105343 | NUCLEOSIDE SUPPLEMENTATION TO PROMOTE CELLULAR FUNCTION, GENETIC STABILITY AND REGENERATIVE APPLICATIONS - In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture media comprise a basal culture medium for stem cells, where the culture medium is supplemented with one or more nucleoside triphosphates (e.g., dNTPs and/or NPs) or one or more precursors thereof. Illustrative NCT media comprise a delivery vehicle (e g. skin creams or other vehicle) containing one or more nucleoside triphosphates (e.g., dNTPs and/or NPs) or one or more precursors thereof. The NCT medium provides, inter alia, direct delivery of nucleoside cocktails into human tissues (such as skin) for regenerative, cosmetic and/or therapeutic purposes. | 2015-04-16 |
20150105344 | ALGIN OLIGOSACCHARIDES AND THE DERIVATIVES THEREOF AS WELL AS THE MANUFACTURE AND THE USE OF THE SAME - The invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedure that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2˜6 and the temperature of 100˜120° C., and adjusted pH to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes. | 2015-04-16 |
20150105345 | USES OF ANTAGONISTS OF HYALURONAN SIGNALING - Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer. | 2015-04-16 |
20150105346 | DEXTRAN-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE - A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum. | 2015-04-16 |
20150105347 | Shape-Changing Droplet - Shape-changing droplets, compositions comprising shape-changing droplets, methods of depositing benefit agents onto substrates using shape-changing droplets, and methods of making shape-changing droplets. | 2015-04-16 |
20150105348 | COMPOSITIONS AND METHODS FOR REDUCING LACTATE LEVELS - The present disclosure provides methods of reducing levels of lactate in a fluid or tissue in an individual. The present disclosure provides pharmaceutical compositions suitable for use in the methods. | 2015-04-16 |
20150105349 | (R)-(-)-1,2-propanediol compositions and methods - Short-chain 2- to 3-carbon alcohols are used as solvents for cooling agents in the preparation of topical therapeutic and cosmetic formulations. Some of these alcohols, especially ethanol, inhibit the ability of the cooling agent to activate its target receptor. In one embodiment of this invention, (R)-1,2-propanediol is used as an alcoholic solvent for the topical delivery of cooling agents to biological surfaces. This (R)-1,2-propanediol enantiomer has a minimum inhibitory effect on cooling with respect to standard 2- to 3-carbon alcoholic solvents, and functions to substantially protect the agents cooling activity from inhibition when in the presence of a short-chain alcohol such as ethanol. | 2015-04-16 |
20150105350 | COMBINATION THERAPY COMPRISING TENOFOVIR ALAFENAMIDE HEMIFUMARATE AND COBICISTAT FOR USE IN THE TREATMENT OF VIRAL INFECTIONS - The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and elvitegravir, and the combination of tenofovir alafenamide hemifumarate, cobicistat, emtricitabine, and darunavir, are disclosed. | 2015-04-16 |
20150105351 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS - The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods for inhibiting reverse transcriptase and treating HIV infections, especially included drug resistant strains of HIV-1 and HIV-2 and/or secondary disease states and/or conditions which occur as a consequence of HIV infection. | 2015-04-16 |
20150105352 | COMBINATION OF AN HMG-COA REDUCTASE INHIBITOR AND A FARNESYL-PYROPHOSPHATASE SYNTHASE INHIBITOR FOR THE TREATMENT OF DISEASES RELATED TO THE PERSISTENCE AND/OR ACCUMULATION OF PRENYLATED PROTEINS - The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing. | 2015-04-16 |
20150105353 | Stable Composition For Controlling Biological Growth and Method For Using Same in Oil Field Applications - A stabilized composition is disclosed which contains at least two biocides, particularly at least two non-oxidizing biocides. In one embodiment, the composition contains a phosphonium sulfate compound combined with a dialkyl dimethyl quaternary amine compound. In order to stabilize the composition, an alkyl trimethyl ammonium compound is added to the composition. In one embodiment, the stabilizing agent produces a single phase composition. With the aid of the stabilizing agent, the single phase concentrated compositions can be produced that can later be diluted for use. In one embodiment, the composition may be used to treat aqueous systems in industrial applications. | 2015-04-16 |
20150105354 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS - Disclosed are compounds of the formula I | 2015-04-16 |
20150105355 | 4-DEDIMETHYLAMINO TETRACYCLINE COMPOUNDS - The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 2015-04-16 |
20150105356 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS - The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered. The subject invention also concerns methods for screening for, assessing risk of developing, and/or diagnosing conditions associated with oxidative stress, such as ulcerative colitis and other inflammatory bowel disorders. | 2015-04-16 |
20150105357 | Lactate-Based Fulvestrant or Fulvestrant Derivative Oily Preparation and Preparation Method Thereof - An oily formulation of fulvestrant or derivatives thereof and a method for producing the same. The oily formulation comprises: fulvestrant or derivatives thereof in an amount of 10 mg/ml to 170 mg/ml; a lactate compound in an amount of 5 to 80% of the total weight of the formulation; a vegetable oil or synthetic oil (ester); an analgesic; and an optional antioxidant. | 2015-04-16 |
20150105358 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS - The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations. | 2015-04-16 |
20150105359 | PHARMACEUTICAL COMPOSITION FOR EMERGENCY CONTRACEPTION - The invention relates to pharmaceutical compositions for emergency contraception, to the use of levonorgestrel in combination with COX inhibitors for the preparation of pharmaceutical compositions for the stated purpose, and to a method for preparing these pharmaceutical compositions. | 2015-04-16 |
20150105360 | Therapeutic Compositions and Method - This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions could be, but are not limited to, alcohol, drugs, caffeine, sugar, food, nicotine, etc. The present invention further relates to the use of cortisol blockers (GR antagonists) for wound healing and transplants, the prevention or treatment of stress induced osteoporosis and the rapid healing of bone related injuries, and regenerative therapy. | 2015-04-16 |
20150105361 | METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE AND POLYCYSTIC LIVER DISEASE - The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell. | 2015-04-16 |
20150105362 | SYNTHESIS OF ESTETROL VIA ESTRONE DERIVED STEROIDS - A process is provided for the making of estetrol starting from a 3-A-oxy-estra-1,3,5(10),15-tetraen-17-one, wherein A is an C | 2015-04-16 |
20150105363 | METHODS AND FORMULATIONS FOR TREATING SCARS AND BETA-CATENIN-MEDIATED DISORDERS - A topical drug composition for treating a β-catenin-mediated disorder in a mammal is provided comprising a Nefopam compound selected from Nefopam, or a functionally equivalent analogue, prodrug, salt or solvate thereof. | 2015-04-16 |
20150105364 | NMDA Receptor Modulators and Uses Thereof - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 2015-04-16 |
20150105365 | HETEROARYL LINKED QUINOLINYL MODULATORS OF RORgammat - The present invention comprises compounds of Formula I. | 2015-04-16 |
20150105366 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2015-04-16 |
20150105367 | RAF INHIBITOR COMPOUNDS - This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers. | 2015-04-16 |
20150105368 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS - The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. | 2015-04-16 |
20150105369 | ALKYL LINKED QUINOLINYL MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2015-04-16 |
20150105370 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS - Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis. | 2015-04-16 |
20150105371 | CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS - This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, | 2015-04-16 |
20150105372 | SECONDARY ALCOHOL QUINOLINYL MODULATORS OF RORyt - The present invention comprises compounds of Formula I. | 2015-04-16 |
20150105373 | NITROGENATED HETEROCYCLIC COMPOUND - The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. | 2015-04-16 |
20150105374 | Substituted annellated pyrimidines and use thereof - The present application relates to novel substituted annellated pyrimidines, methods for production thereof, use thereof alone or in combinations for treating and/or preventing diseases and use thereof for the production of medicinal products for treating and/or preventing diseases, in particular for treating and/or preventing cardiovascular diseases. | 2015-04-16 |
20150105375 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C - This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 | 2015-04-16 |
20150105376 | QUINOLINONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE - The present invention provides compounds of Formula (I): | 2015-04-16 |
20150105377 | Methods and Compositions for RAF Kinase Mediated Diseases - The invention discloses methods and compositions for treating or preventing RAF kinase mediated diseases or conditions by administering a compound of Formula 1: or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein the variables are defined as herein. | 2015-04-16 |
20150105378 | PYRROLINONE CARBOXAMIDE COMPOUNDS USEFUL AS ENDOTHELIAL LIPASE INHIBITORS - The present invention provides compounds of Formula (I) or Formula (III): | 2015-04-16 |
20150105379 | SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING BETA SECRETASE INHIBITORY ACTIVITY - The following compound is provided as an agent for treating a disease induced by production, secretion and/or deposition of amyloid β protein, for example,
| 2015-04-16 |
20150105380 | METHODS AND USES OF COMPOUNDS FOR TREATING DISEASE - The present invention provides methods for treating polycystic kidney disease by administering a compound or pharmaceutical composition thereof having the general structural formula (I) | 2015-04-16 |
20150105381 | SUBSTITUTED PYRAZOLOQUINAZOLINONES AND PYRROLOQUINAZOLINONES AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS - The present invention relates to the pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (I), as well as pharmaceutical compositions containing them, and their use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate level or signalling in mammals, in particular their use in the treatment and/or prophylaxis of acute and chronic neurological and/or psychiatric disorders. | 2015-04-16 |
20150105382 | PYRIMIDINE SUBSTITUTED PURINE COMPOUNDS AS KINASE (S) INHIBITORS - The present invention relates to a purine compound useful as a kinase inhibitor. The compound has the structure: | 2015-04-16 |
20150105383 | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma - The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a PI3K inhibitor. | 2015-04-16 |
20150105384 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS - Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof. | 2015-04-16 |
20150105385 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. | 2015-04-16 |
20150105386 | 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS - The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R | 2015-04-16 |
20150105387 | SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS - Compounds of formula (1) | 2015-04-16 |
20150105388 | CARBOXAMIDE-SUBSTITUTED HETEROARYL-PYRAZOLES AND THE USE THEREOF - This invention relates to new carboxamide-substituted heteroaryl-pyrazoles, method for their production, their use for the treatment and/or prophylaxis of diseases, as well as their use for the production of pharmaceutical agents for the treatment and/or prophylaxis of diseases, in particular retroviral diseases, in humans and/or animals. | 2015-04-16 |
20150105389 | 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS - Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RC kinase-mediated disorder, disease, or condition. | 2015-04-16 |
20150105390 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof. | 2015-04-16 |
20150105391 | SMALL MOLECULE MODIFIERS OF THE HEC1-NEK2 INTERACTION IN G2/M - Certain embodiments of the present invention provide selected compounds having a molecular structure according to Formula 1: | 2015-04-16 |
20150105392 | DUAL-ACTING THIOPHENE, PYRROLE, THIAZOLE AND FURAN ANTIHYPERTENSIVE AGENTS - In one aspect, the invention relates to compounds having the formula: | 2015-04-16 |
20150105393 | AMIDE DERIVATIVES AS TTX-S BLOCKERS - The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved. | 2015-04-16 |
20150105394 | CYCLOLIC HYDRAZINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS - Compounds of Formula I are provided, including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: wherein Z is selected from the group consisting of: which are useful as HIV attachment inhibitors. | 2015-04-16 |
20150105395 | ACTIVATORS OF HUMAN PYRUVATE KINASE - Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R | 2015-04-16 |
20150105396 | Chemical Compounds - The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): | 2015-04-16 |